

## Upper Payment Limit (UPL) Benchmarks - Enbrel Cost and Price Metrics


The graphs below are prepared by staff to help the Board visualize the different cost and price metrics for Enbrel and its therapeutic alternatives (TAs). The first graph outlines the price and cost metrics for Enbrel, while the remaining graphs present one price and cost metric specifically, and compare Enbrel with its TAs.

The graphs include data from the Colorado All Payer Claims Database (CO APCD) and the following price benchmarks:

- Acquisition Costs
- Public Fee Schedules, Maximum Fair Price (MFP), and Net Price (*confidential*)
- Average out-of-pocket amounts
- Age Distribution of Enbrel Utilizers by Payer Type (*newly added on August 19*)


The graphs align with the data in the “Summary” tab of the Excel workbook. Biosimilars have been grouped together, but each is still shown on the graphs to demonstrate the price and cost variability.

## Enbrel Cost and Price Metrics




WAC - Data is confidential and only shared with the Board


### National Average Drug Acquisition Cost (NADAC)




### Colorado Average Acquisition Cost (AAC)



## Big 4




## Federal Supply Schedule




Net Price - Data is confidential and only shared with the Board


## Average Total Paid PPPY






## Average Plan Paid PPPY




## Average Total OOP





### Age Distribution of Enbrel Utilizers by Payer Type



It is important to note that the upper payment limit (UPL) methodology must consider the impact of the UPL methodology to older adults and shall not place a lower value on their lives, per section 10-16-1407-(3) and PDAB Rule, 3 CCR 702-9, Part 4.1.C. Older adults are defined in the PDAB Policy 05 as individuals aged 65 and older.